These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34589050)

  • 1. Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants-A Potential Novel Biomarker of Disease Activity.
    Stascheit F; Hotter B; Klose S; Meisel C; Meisel A; Klehmet J
    Front Neurol; 2021; 12():723009. PubMed ID: 34589050
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.
    Hayashi T; Nukui T; Piao JL; Sugimoto T; Anada R; Matsuda N; Yamamoto M; Konishi H; Dougu N; Nakatsuji Y
    Brain Behav; 2021 May; 11(5):e02084. PubMed ID: 33617139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.
    van Lieverloo GGA; Wieske L; Verhamme C; Vrancken AFJ; van Doorn PA; Michalak Z; Barro C; van Schaik IN; Kuhle J; Eftimov F
    J Peripher Nerv Syst; 2019 Jun; 24(2):187-194. PubMed ID: 30973667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy.
    Klehmet J; Beutner S; Hoffmann S; Dornauer M; Paul F; Reilmann R; Brandt AU; Meisel A
    BMC Neurol; 2019 Jun; 19(1):118. PubMed ID: 31176377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy.
    Bjelica B; Peric S; Gwathmey K; Sadjadi R; Bozovic I; Burns TM; Basta I
    J Peripher Nerv Syst; 2019 Sep; 24(3):247-252. PubMed ID: 31209940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased muscle echointensity correlates with clinical disability and muscle strength in chronic inflammatory demyelinating polyneuropathy.
    Fisse AL; Fiegert S; Stoykova Z; Brünger J; Athanasopoulos D; Grüter T; Motte J; Gold R; Pitarokoili K
    Eur J Neurol; 2021 May; 28(5):1698-1705. PubMed ID: 33404183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum levels of endothelin-1 in patients with chronic inflammatory demyelinating polyneuropathy.
    Chang CW; Wu HC; Lyu RK; Lo YS; Chen CM; Ro LS; Chang HS; Huang CC; Liao MF; Wu YR; Kuo HC; Chu CC; Weng YC; Wei PT; Lo AL; Chang KH
    Clin Chim Acta; 2018 Jan; 476():49-53. PubMed ID: 29137897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Axonal damage determines clinical disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A prospective cohort study of different CIDP subtypes and disease stages.
    Grüter T; Motte J; Bulut Y; Kordes A; Athanasopoulos D; Fels M; Schneider-Gold C; Gold R; Fisse AL; Pitarokoili K
    Eur J Neurol; 2022 Feb; 29(2):583-592. PubMed ID: 34687104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the Serbian version of inflammatory Rasch-built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Peric S; Bozovic I; Pruppers MHJ; Bjelica B; Stevic Z; Faber CG; Merkies ISJ; Basta I
    J Peripher Nerv Syst; 2019 Sep; 24(3):260-267. PubMed ID: 31397933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of anti-ganglioside antibodies by a line immunoassay in patients with chronic-inflammatory demyelinating polyneuropathies (CIDP).
    Klehmet J; Märschenz S; Ruprecht K; Wunderlich B; Büttner T; Hiemann R; Roggenbuck D; Meisel A
    Clin Chem Lab Med; 2018 May; 56(6):919-926. PubMed ID: 29329103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes.
    Alabdali M; Abraham A; Alsulaiman A; Breiner A; Barnett C; Katzberg HD; Lovblom LE; Perkins BA; Bril V
    J Neurol Sci; 2017 Jan; 372():223-227. PubMed ID: 28017218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological spontaneous activity as a prognostic marker in chronic inflammatory demyelinating polyneuropathy.
    Grüter T; Motte J; Fisse AL; Bulut Y; Köse N; Athanasopoulos D; Otto S; Yoon MS; Schneider-Gold C; Gold R; Pitarokoili K
    Eur J Neurol; 2020 Dec; 27(12):2595-2603. PubMed ID: 32794258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.
    Godelaine J; De Schaepdryver M; Bossuyt X; Van Damme P; Claeys KG; Poesen K
    Brain Commun; 2021; 3(1):fcab018. PubMed ID: 33796853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years.
    Hiew FL; Ong JJ; Viswanathan S; Puvanarajah S
    J Clin Neurosci; 2018 Apr; 50():203-207. PubMed ID: 29398193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Fecal Calprotectin an Applicable Biomarker of Gut Immune System Activation in Chronic Inflammatory Demyelinating Polyneuropathy? - A Pilot Study.
    Koszewicz M; Mulak A; Dziadkowiak E; Budrewicz S
    Front Hum Neurosci; 2021; 15():733070. PubMed ID: 34867240
    [No Abstract]   [Full Text] [Related]  

  • 16. Impairment and disability in 20 CIDP patients according to disease activity status.
    Panaite PA; Renaud S; Kraftsik R; Steck AJ; Kuntzer T
    J Peripher Nerv Syst; 2013 Sep; 18(3):241-6. PubMed ID: 24028192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of tremor on disability assessment in chronic inflammatory demyelinating polyradiculoneuropathy.
    van Veen R; Pallada G; Wieske L; Ten Holter SEM; van Rootselaar AF; Verhamme C; de Bie RMA; van Schaik IN; Merkies ISJ; Dijk JM; Eftimov F
    J Peripher Nerv Syst; 2023 Mar; 28(1):58-68. PubMed ID: 36571466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease activity in chronic inflammatory demyelinating polyneuropathy: A comparative study of clinical and skin biopsy markers.
    Acarli ANÖ; Ünverengil G; Şirin NG; Çakar A; Durmuş H; Parman Y
    Muscle Nerve; 2022 Dec; 66(6):736-743. PubMed ID: 36151750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatigue in chronic inflammatory demyelinating polyneuropathy.
    Gable KL; Attarian H; Allen JA
    Muscle Nerve; 2020 Dec; 62(6):673-680. PubMed ID: 32710648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Bozovic I; Kacar A; Peric S; Nikolic A; Bjelica B; Cobeljic M; Petrovic M; Stojanov A; Djuric V; Stojanovic M; Djordjevic G; Martic V; Dominovic A; Vukojevic Z; Basta I
    J Neurol; 2017 Dec; 264(12):2481-2486. PubMed ID: 29086018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.